![](https://impactbiotech.com/wp-content/uploads/2023/05/ImPact-background-picture.png)
About ImPact Biotech
ImPact Biotech is focused on the development and launch of Padeliporfin VTP Therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Israel, with divisions in USA and France as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel.
Leadership